SCHEMBL30184109

CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](N)CS)C(C)C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)O)C(C)C

nearest known ligand 0.52

Predicted protein targets (top 7)

	gene	UniProt	supporting neighbours	confidence
▸	CALCR	P30988	4/20	0.52

▸	GLP1R	P43220	9/20	0.51

▸	SCTR	P47872	1/20	0.51

▸	BACE1	P56817	2/20	0.49

▸	BACE2	Q9Y5Z0	2/20	0.49

▸	F2	P00734	2/20	0.48

▸	TFPI	P10646	1/20	0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30865073	0.98	CALCR (0.53)	CALCRGLP1RSCTRBACE1BACE2
SCHEMBL30865076	0.93	CALCR (0.52)	CALCRGLP1RSCTRBACE1BACE2
SCHEMBL30184274	0.93	CALCR (0.52)	CALCRGLP1RSCTRBACE1BACE2
SCHEMBL30746744	0.90	CALCR (0.58)	CALCRGLP1RSCTRF2TFPI
SCHEMBL31690549	0.89	GLP1R (0.61)	CALCRGLP1RSCTRTFPI
SCHEMBL31385184	0.88	CALCR (0.56)	CALCRGLP1RSCTRBACE1F2
SCHEMBL34460636	0.88	CALCR (0.59)	CALCRGLP1RSCTRF2TFPI
SCHEMBL30102559	0.86	CALCR (0.56)	CALCRGLP1R
SCHEMBL29692930	0.86	CALCR (0.56)	CALCRGLP1R
SCHEMBL30175851	0.86	GLP1R (0.61)	GLP1RSCTRTFPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-12551537-B2	Methods and compositions for the treatment and prevention of type 1 diabetes	DR. MARY MORRIS & ASSOCIATES, LLC (US)	2026-02-17	—	—	US	disclosed
US-20230018324-A1	METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF TYPE 1 DIABETES	DR. MARY MORRIS & ASSOCIATES, LLC (US)	2023-01-19	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-12551537-B2	Methods and compositions for the treatment and prevention of type 1 diabetes	IAPP, GLP1R, SLC5A1	CALCR 384/4885GLP1R 2/4885SCTR 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.